Evolent Health Inc

EVH remains in a Stage 2 advancing regime with a clear higher-highs/higher-lows sequence above rising EMAs, but price is extended into extreme overbought territory and testing the 200-day SMA, with a recent exhaustion candle highlighting near-term momentum fatigue. Immediate entries are unfavorable; we will stalk for a corrective pullback into rising EMAs or the 50-day SMA support zone before initiating long exposure.

• ↑Q1 2026 revenue of $496 M (+9% sequential) beats outlook.
• ↑Guiding $2.4–2.6 B 2026 revenue on new oncology contracts.
• ↓Negative profitability factors and earnings yield indicate inefficiencies.